Pharmaceutical sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd. Clinical Trials
Studies where Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 23Pancreatic Cancer
A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
HRS-4642-103 is a single-center, single-arm, open-label, fixed-sequence study to investigate the effect of Itraconazole on the pharmacokinetics of HRS-4642 following intravenous infusion in healthy participants.
- Trial name
- NCT07906691
- Testing
- HRS4642, Itraconazole Capsules
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Systemic Treatment-naïve Pancreatic Cancer
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
The study is being conducted To evaluate the efficacy of HRS-4642 in combination with gemcitabine plus nab-paclitaxel (AG) (± SHR-1316) versus standard therapy in participants, high-risk resectable/borderline resectable…
- Trial name
- NCT07900789
- Testing
- HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- Where
- 2 sites in China
- Volunteers
- 825 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Limited-stage Small-cell Lung Cancer
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung…
- Trial name
- NCT07798947
- Testing
- SHR-7787 Injection, SHR-1316
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors.
- Trial name
- NCT06605222
- Testing
- SHR-7787 injection
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors.
- Trial name
- NCT06417554
- Testing
- SHR-A2102, SHR-A2102 ; Adebrelimab injection, SHR-A2102 + Disitamab Vedotin For Injection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Multiple Myeloma
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
- Trial name
- NCT07490613
- Testing
- SHR-3836 administered as multiple doses.
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
- Trial name
- NCT06649292
- Testing
- SHR-A1904, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
- Trial name
- NCT06474455
- Testing
- SHR-9839 for Injection, SHR-A1921 for Injection, SHR-A2009 for Injection
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Patients With Advanced or Metastatic Malignant Tumors
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion.
- Trial name
- NCT07073534
- Testing
- SHR-1501, Adebrelimab
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Pancreatic Cancer With
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid…
- Trial name
- NCT07296341
- Testing
- HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine, HRS-4642;nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.